Tirzepatide: what this dual GIP/GLP-1 agonist actually is
The short version: a once-weekly injection that mimics two gut hormones at the same time.
TL;DR
- Tirzepatide is a dual-agonist injection that copies both GLP-1 and GIP.
- It is sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management).
- Branded tirzepatide is FDA-approved; compounded tirzepatide is not.
What it is
Tirzepatide is a long-acting peptide injection that activates two gut-hormone receptors at once: GLP-1 and GIP (in plain English: glucose-dependent insulinotropic polypeptide, another hormone your gut releases after eating). It was approved by the FDA in 2022 as Mounjaro for type 2 diabetes and in 2023 as Zepbound for chronic weight management. Both are made by Eli Lilly. Compounded tirzepatide is prepared by 503A pharmacies and is not itself FDA-approved.
How it works
Picture two doorbells on the same front door — one labeled GLP-1, one labeled GIP. Tirzepatide rings both at once. Activating the GLP-1 doorbell slows the stomach, signals fullness, and helps the pancreas release insulin only when blood sugar is high. The GIP doorbell adds an insulin-release boost and may improve how fat tissue handles fuel. The combined effect is more glucose control and more appetite reduction than activating GLP-1 alone, at least in the trials run so far (Jastreboff et al., NEJM, 2022).
Who asks about it
People ask this when they have heard of Mounjaro or Zepbound and want to know how they differ from semaglutide-based products like Ozempic and Wegovy. The short answer is one extra receptor target and a different molecule.
What the research says
In the SURMOUNT-1 trial, adults without diabetes who took tirzepatide for 72 weeks lost on average about 1 in 5 pounds of starting body weight at the highest dose, compared with about 1 in 30 on placebo (Jastreboff et al., NEJM, 2022). Side effects were similar to other GLP-1 medications: nausea, diarrhea, and injection-site reactions, mostly during dose escalation.
What to know before considering it
Tirzepatide is a prescription medication that requires clinician evaluation, baseline labs, and ongoing monitoring. Side effects are common, especially during the first few weeks. Compounded tirzepatide carries the additional consideration that the compounded preparation is not FDA-approved.
The Halftime POV
Tirzepatide is the most-studied dual-agonist on the market and the reason “GLP-1” is no longer a single-receptor story. The science is interesting; the access landscape is messier. We treat both honestly.
Related reading:
- GLP-1: what this gut hormone actually does
- Compounded semaglutide: what it is and how it differs from branded
- Novo Nordisk v. Hims & Hers: the compounded GLP-1 case
FAQ
Q: What is tirzepatide? A: Tirzepatide is a once-weekly injection that copies two gut hormones at once: GLP-1 and GIP. Branded as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, both FDA-approved by Eli Lilly.
Q: How is tirzepatide different from semaglutide? A: Semaglutide copies one gut hormone (GLP-1). Tirzepatide copies two (GLP-1 and GIP). In the SURMOUNT-1 trial, tirzepatide produced greater average weight loss than semaglutide had in earlier trials, though the studies were not head-to-head.
Q: Is compounded tirzepatide FDA-approved? A: No. Branded Mounjaro and Zepbound are FDA-approved. Compounded tirzepatide prepared by a 503A pharmacy is not FDA-approved and is the subject of ongoing litigation.
Disclaimer
This article is educational and is not medical advice. Compounded GLP-1 medications are prepared by state-licensed 503A compounding pharmacies from FDA-approved active pharmaceutical ingredients and are not themselves FDA-approved. GLP-1 therapies are available only with a valid prescription following a licensed clinician evaluation. Clinical outcomes depend on individual factors including baseline health, adherence, diet, and physical activity. Individual results vary. Side effects are common and may include nausea, injection-site reactions, and gastrointestinal symptoms. Compounded GLP-1 products are the subject of ongoing litigation (Novo Nordisk v. Hims & Hers, Feb 2026). Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
